Dermata Therapeutics Statistics
Total Valuation
DRMA has a market cap or net worth of $1.94 million. The enterprise value is -$2.80 million.
| Market Cap | 1.94M |
| Enterprise Value | -2.80M |
Important Dates
The last earnings date was Wednesday, May 15, 2024, after market close.
| Earnings Date | May 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DRMA has 444,056 shares outstanding. The number of shares has increased by 575.65% in one year.
| Shares Outstanding | 444,056 |
| Shares Change (YoY) | +575.65% |
| Shares Change (QoQ) | +127.77% |
| Owned by Insiders (%) | 3.85% |
| Owned by Institutions (%) | 2.93% |
| Float | 399,415 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.51 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -141.30% and return on invested capital (ROIC) is -235.50%.
| Return on Equity (ROE) | -141.30% |
| Return on Assets (ROA) | -119.00% |
| Return on Capital (ROIC) | -235.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.09M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -89.59% in the last 52 weeks. The beta is 0.89, so DRMA's price volatility has been lower than the market average.
| Beta (1Y) | 0.89 |
| 52-Week Price Change | -89.59% |
| 50-Day Moving Average | 5.55 |
| 200-Day Moving Average | 9.97 |
| Relative Strength Index (RSI) | 37.07 |
| Average Volume (30 Days) | 10,026 |
Short Selling Information
The latest short interest is 80,354, so 18.10% of the outstanding shares have been sold short.
| Short Interest | 80,354 |
| Short Previous Month | 77,571 |
| Short % of Shares Out | 18.10% |
| Short % of Float | 20.12% |
| Short Ratio (days to cover) | 0.47 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.97M |
| Pretax Income | -8.69M |
| Net Income | -8.69M |
| EBITDA | -8.69M |
| EBIT | -8.69M |
| Earnings Per Share (EPS) | -$27.75 |
Balance Sheet
The company has $4.73 million in cash and no debt, giving a net cash position of $4.73 million or $10.66 per share.
| Cash & Cash Equivalents | 4.73M |
| Total Debt | n/a |
| Net Cash | 4.73M |
| Net Cash Per Share | $10.66 |
| Equity / Book Value | 3.81M |
| Book Value Per Share | 8.58 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | -7.46M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.46M |
| FCF Per Share | -$16.81 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRMA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -575.65% |
| Shareholder Yield | -575.65% |
| Earnings Yield | -448.79% |
| FCF Yield | -385.52% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 16, 2024. It was a reverse split with a ratio of 1:15.
| Last Split Date | May 16, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |